These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1331414)

  • 1. Antinociceptive mechanisms of [D-Arg2]-dermorphin tripeptide analogs.
    Sakurada S; Chaki K; Watanabe H; Nakata N; Sakurada T; Kisara K; Suzuki K
    J Pharmacol Exp Ther; 1992 Nov; 263(2):793-9. PubMed ID: 1331414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid activities of D-Arg2-substituted tetrapeptides.
    Sato T; Sakurada S; Sakurada T; Furuta S; Chaki K; Kisara K; Sasaki Y; Suzuki K
    J Pharmacol Exp Ther; 1987 Aug; 242(2):654-9. PubMed ID: 3612556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
    He L; Lee NM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
    Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
    Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
    Hammond DL; Wang H; Nakashima N; Basbaum AI
    J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
    Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY; Yang HH; Li S; Adams JU
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.
    Mizoguchi H; Watanabe C; Watanabe H; Moriyama K; Sato B; Ohwada K; Yonezawa A; Sakurada T; Sakurada S
    Eur J Pharmacol; 2007 Apr; 560(2-3):150-9. PubMed ID: 17307162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
    Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
    J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermenkephalin (Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2): a potent and fully specific agonist for the delta opioid receptor.
    Amiche M; Sagan S; Mor A; Delfour A; Nicolas P
    Mol Pharmacol; 1989 Jun; 35(6):774-9. PubMed ID: 2543911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
    Cahill CM; White TD; Sawynok J
    J Pharmacol Exp Ther; 1995 Oct; 275(1):84-93. PubMed ID: 7562600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta and mu opioid receptors from the brain of a urodele amphibian, the rough-skinned newt Taricha granulosa: cloning, heterologous expression, and pharmacological characterization.
    Bradford CS; Walthers EA; Stanley DJ; Baugh MM; Moore FL
    Gen Comp Endocrinol; 2006 May; 146(3):275-90. PubMed ID: 16375901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid binding to rat and guinea-pig neural membranes in the presence of physiological cations at 37 degrees C.
    Werling LL; Zarr GD; Brown SR; Cox BM
    J Pharmacol Exp Ther; 1985 Jun; 233(3):722-8. PubMed ID: 2989494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
    Mitrovic I; Napier TC
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.
    Bilsky EJ; Bernstein RN; Hruby VJ; Rothman RB; Lai J; Porreca F
    J Pharmacol Exp Ther; 1996 Apr; 277(1):491-501. PubMed ID: 8613959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.